首页 > 市场调查报告书 > 医疗设备

医学影像诊断 CT/MRI/X光

市场调查报告书

商品编码

1143395

正电子发射断层扫描 (PET) 全球市场-2022-2029

Global Positron-Emission Tomography (PET) Market - 2022-2029

出版日期: 2022年10月26日 | 出版商:

DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

在预测期间（2022-2029 年），正电子发射断层扫描 (PET) 市场规模预计将以 4.78% 的复合年增长率增长。

正电子发射断层扫描 (PET) 是核医学中的一种功能成像技术，用于观察体内的代谢过程，以帮助诊断疾病。与成熟的 PET 相比，PET 具有显着优势，例如出色的对比度和分辨率，以及减少的电离辐射。

市场动态

由于放射性药物对 PET 分析的需求增加、宠物成像技术进步以及各种慢性病发病率上升等因素，PET（正电子发射断层扫描）市场正在增长。

不断增长的研发和市场开发正在推动全球市场的增长。

正电子发射断层扫描 (PET) 可以以高分辨率和灵敏度测量生物系统中的功能过程。生物学和放射化学的最新进展使 PET 可用于研究许多功能过程。此外，研发和市场开发的进步正在推动全球市场的增长。例如，2022 年 7 月 20 日，被誉为创新 PET 放射性药物开发和商业化领导者的 Bracco, Inc.、Blue Earth Diagnostics, Inc. 宣布，它将有效治疗接受雄激素剥夺治疗的前列腺癌患者(ADT). 介绍了两项回顾性研究的结果，该研究评估了 Axumin（Fluciclovine F18）在生化復发男性 PET 成像中的应用，均显示 Axumin 性能和 ADT 持续时间没有差异，也影响 Axumin 检出率，但结果显示没有差异。此外，2022 年 7 月 19 日， Radialis 获得美国 FDA 的批准，可在美国市场销售器官靶向 PET 设备 Radialis PET Imager。

缺乏适当的报销政策阻碍了全球市场的增长。

缺乏足够的报销政策导致付款人拒绝在全球范围内对 PET 和 SPECT 程序进行报销。此外，放射性药物的半衰期短，使整个过程的成本效益降低，减缓了全球市场的增长。

行业分析

本报告基于波特五力、创新、新产品发布和定价等各种行业因素，对全球正电子发射断层扫描 (PET) 市场进行了深入分析。

细分分析

在预测期内（2022-2029 年），肿瘤领域预计将主导全球市场。

由于正电子 CT (PET CT) 是一种有效的核成像技术，用于确认各种癌症的存在，肿瘤学领域在 2021 年占据了市场主导地位。在肿瘤学中，PET（正电子 CT）使用 FDG（18Fluorine-2-Deoxy-d-glucose）作为放射性药物，以证明与正常细胞相比，恶性细胞的代谢增加。随着全球癌症患病率的上升，对先进诊断成像技术的需求不断增加，市场也在不断扩大。PET和PET/CT检查占肿瘤科80%以上，心脏病科和神经科各占5%左右。此外，世界上癌症发病率的增加增加了肿瘤学领域在全球市场中的主导地位。例如，全球癌症观察站的统计数据显示，2020年将有19,292,789例新发各类癌症病例，共有9,958,133人死于不同类型的癌症。因此，对癌症患者的早期诊断和治疗的需求增加了 PET 扫描仪的使用，从而导致市场增长。

区域分析

据估计，北美将主导全球 PET（正电子发射断层扫描）市场。

北美预计将在 2021 年主导正电子发射断层扫描 (PET) 市场，并在预测期内（2022-2029 年）保持增长，美国癌症患病率上升，PET 扫描数量正在增加，製造商正在引入新设备用于成像。美国每年进行大约 200 万次 PET 扫描。因为慢性病和癌症病例在美国呈上升趋势。例如，根据美国国家癌症研究所的数据，2020 年将有超过 1,806,590 例新发癌症和 606,520 例癌症死亡病例。根据美国癌症协会的数据，到 2021 年，将有近 190 万例新诊断和 608,570 例死亡。而美国疾病控制与预防中心预测，到 2040 年，将有 2950 万例癌症诊断。此外，Positron Corporation、Segami Corporation、Naviscan Inc、MedX Holdings Inc 和 GE Healthcare 等主要市场份额参与者的存在确保了北美在全球市场的领导地位。

竞争格局

市场上的主要主要参与者有 GE Healthcare、Philips Healthcare、Siemens Healthcare、Positron Corporation、Segami Corporation、Spectrum Dynamics Ltd.、Naviscan Inc.、MedX Holdings Inc.、United Imaging、Neusoft Medical Systems等。主要参与者采取了各种增长战略，如新产品发布、併购、合作伙伴和联盟，为全球正电子发射断层扫描 (PET) 市场的增长做出了贡献。例如，2022 年 8 月 9 日，GE Healthcare 与 Nex Cubed 合作，为在加拿大推出的 Edison Accelerator 选择了六家数字健康初创公司。同样在 2022 年 4 月 1 日，GE Healthcare 将在印度开设一家新的製造工厂。

GE医疗

概述

GE Healthcare 成立于 2004 年，总部位于美国伊利诺伊州芝加哥市。它是美国跨国集团通用电气的子公司。一家生产和销售医疗诊断成像设备和放射性药物的大型公司。

产品介绍

GE Healthcare 的正电子发射断层扫描 (PET) 产品组合包括 Discovery IQ、Discovery MI Gen 2、MotionFree、NM 830、NM/CT 850、NM/CT 860、NM/CT 870 DR、NM/CT 870 CZT 等。

该报告提供对全球正电子 CT (PET) 市场的大约40 多个市场数据表、45 多个图表和 200 页（大约）的访问。

Market Overview

Positron-Emission Tomography (PET) Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.78% during the forecast period (2022-2029).

Positron-Emission Tomography (PET) is a nuclear medicine functional imaging technique used to observe the metabolic process in the body as an aid to the diagnosis of disease. PET offers significant advantages, including excellent contrast and resolution and reduced ionizing radiation, compared to well-established PET.

Market Dynamics

The positron-emission tomography (PET) market is growing due to several factors, such as rising demand for PET analysis in radiopharmaceuticals, technological advancements in pet imaging, and rising incidence of various chronic diseases.

The growing research and market developments are fueling global market growth.

Positron Emission Tomography (PET) enables a high resolution and high-sensitivity measurement of the biological system's functional processes. The latest advancements in biology and radio-chemistry allowed for the utilization of PET for studying a large number of functional processes. Furthermore, the growing research and market developments are fueling the global market growth; for instance, on July 20, 2022, Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals published the results of two retrospective studies for the evaluation of Axumin (fluciclovine F 18) use for PET imaging in men with biochemical recurrence of prostate cancer who were undergoing androgen deprivation therapy (ADT) and both of which showed that there was no difference in Axumin performance and that the length of time on ADT did not influence Axumin detection rates. Moreover, on July 19, 2022, Radialis Inc. received approval from US FDA to market the Radialis PET Imager, an organ-targeted positron emission tomography (PET) system in the United States market.

The lack of proper reimbursement policies is hampering the global market growth.

Lack of proper reimbursement policies causes rejection of payer's reimbursement for PET and SPECT procedures globally; also, the short half-life of radiopharmaceuticals makes the whole procedure cost ineffective, slowing the global market growth.

Industry Analysis

The global positron-emission tomography (PET) market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, Etc.

Segment Analysis

The oncology segment is predicted to dominate the global market during the forecast period (2022-2029).

The oncology segment subjugated the market in 2021, as positron emission tomography (PET CT) is an effective nuclear imaging technique used to confirm the presence of various cancers. In oncology, PET (positron emission tomography) uses FDG (18Fluorine-2-fluoro-2-Deoxy-d-glucose) as the radiopharmaceutical, demonstrating the increased metabolism by malignant cells when compared to that of normal cells. With the rising incidence of cancer globally, the demand for advanced imaging techniques is growing, resulting in market growth. Oncology accounts for more than 80% of the PET and PET/CT procedures performed, whereas cardiology and neurology account for about 5% each. Furthermore, the growing incidence of cancer globally is driving the dominance of the oncology segment over the global market. For instance, the statistics from the Global Cancer Observatory indicate that in 2020, there were 19,292 789 new cases of all types of cancer, and a total of 9,958,133 deaths were because of different types of cancer. Thus, the need for early diagnosis and treatment of cancer cases has enhanced PET scanners' usage and led to market growth.

Geographical Analysis

North America is estimated to subjugate the global positron-emission tomography (PET) market.

North America dominated the positron-emission tomography (PET) market in 2021 and is expected to maintain the growth over the forecast period (2022-2029), increasing the prevalence of cancer in the United States, rising number of PET scans, and the introduction of new devices for the imaging by manufacturers. The volume of PET procedures in the United States is approximately two million per year. Because of the increasing cases of chronic diseases and cancer in the United States. For instance, according to the National Cancer Institute, in 2020, over 1,806,590 new cancers and 606,520 cancer deaths were registered. In addition, as per the American Cancer Society, in 2021, nearly 1.9 million new diagnoses and 608,570 deaths were registered. Also, according to the CDC's prediction, by 2040, there will be 29.5 million cancer diagnoses. Furthermore, the presence of key market players that hold a major market share, such as Positron Corporation, Segami Corporation, Naviscan Inc, MedX Holdings Inc. and GE Healthcare, ensure the command of North America over the global market.

Competitive Landscape

The market's major key players are Some of the major manufacturers in the positron-emission tomography (PET) market are GE Healthcare, Philips Healthcare, Siemens Healthcare, Positron Corporation, Segami Corporation, Spectrum Dynamics Ltd., Naviscan Inc, MedX Holdings Inc., United Imaging, Neusoft Medical Systems, among others. The key players are adopting various growth strategies such as new product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the global positron-emission tomography (PET) market. For instance, on August 09, 2022, GE Healthcare collaborated with Nex Cubed to select six digital health start-ups for the inaugural Edison Accelerator in Canada. Also, on April 01, 2022, GE Healthcare inaugurated its new manufacturing plant in India.

GE Healthcare

Overview:

GE Healthcare is headquartered in Chicago, Illinois, United States, founded in 2004. It is a subsidiary of American Multinational Conglomerate General Electric. It is a leading manufacturer and distributor of diagnostic imaging and radiopharmaceuticals for imaging modalities used in medical imaging procedures.

Product Portfolio:

GE Healthcare's product portfolio for positron-emission tomography (PET) has Discovery IQ, Discovery MI Gen 2, MotionFree, NM 830, NM/CT 850, NM/CT 860, NM/CT 870 DR, NM/CT 870 CZT, Etc.

The global positron-emission tomography (PET) market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Innovations and Developments
  - 4.1.1.2. Market Developments
- 4.1.2. Restraints
  - 4.1.2.1. Lack of Proper Reimbursement Policies
  - 4.1.2.2. Lack of Skilled Professionals
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
- 7.1.2. Market Attractiveness Index, By Product Type Segment
7.2. Full-Ring PET Scanners
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Partial Ring PET Scanners

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
- 8.1.2. Market Attractiveness Index, By Application Segment
8.2. Cardiology
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Neurology
8.4. Oncology
8.5. Others

By End User

8.6. Introduction
- 8.6.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
- 8.6.2. Market Attractiveness Index, By End User Segment
8.7. Hospitals
- 8.7.1. Introduction
- 8.7.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.8. Diagnostic Centers
8.9. Academic & Research Centers
8.10. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. The U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. The U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. Australia
  - 9.5.6.5. Rest of Asia Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Key Developments and Strategies
10.2. Company Share Analysis
10.3. Product Benchmarking

11. Company Profiles

11.1. GE Healthcare
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Philips Healthcare
11.3. Siemens Healthcare
11.4. Positron Corporation
11.5. Segami Corporation
11.6. Spectrum Dynamics Ltd.
11.7. Naviscan Inc
11.8. MedX Holdings Inc.
11.9. United Imaging
11.10. Neusoft Medical Systems

LIST NOT EXHAUSTIVE